Ningbo Menovo Pharmaceutical Co., Ltd (hereinafter referred to as "Menovo", stock code: 603538), founded in 2004, is a comprehensive pharmaceutical enterprise that integrates the research and development, pilot experiments, production and sales of pharmaceutical intermediates, APIs and finished dosage forms. It is headquartered in the national high-tech zone of Ningbo, with three strategic holding companies, seven wholly-owned subsidiaries in Anhui and Zhejiang province, one Sino-European joint venture pharmaceutical company, two provincial pharmaceutical research institutes (technical centers) and one formulations R&D center, and offices in India, US and Europe. Menovo is one of the top 100 manufacturing and competitive enterprises in Ningbo and one of the top 10 pharmaceutical enterprises with total assets of over 2 billion yuan and more than 1,900 employees. Menovo listed on the main board of the Shanghai Stock Exchange on April 7, 2017.
Year Established: 2004
Business Type: Manufacturer
R&D Capacity: OEM
Main Sales Markets : Central/South America,Western Europe,Eastern Europe,Asia,Middle East
Subscribe to the latest newsletter of Virtual Expo Connect